Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced ...
Viking Therapeutics (VKTX) announced that final results from the company’s Phase 2b clinical trial of VK2809, the company’s novel ...
Seeking Alpha on MSN9h
Viking phase 2b study of NASH candidate hits primary endpointA phase 2b trial of Viking Therapeutics' (NASDAQ:VKTX) VK2809 found that those on the medicine saw statistically significant ...
Viking Therapeutics (VKTX) announced that results from the company’s Phase 2b clinical trial of VK2809, the company’s novel liver-selective ...
Dolby Laboratories (NYSE: DLB) rose 11% after it reported fourth quarter results that beat analysts' estimates on the bottom line. On a non-GAAP basis, f ...
Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced ...
Equity markets have performed well in 2024, but their showing pales next to that of Viking Therapeutics (NASDAQ: VKTX), a mid ...
The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone ...
Viking's leading candidate isn't the only reason to consider the stock. The company's VK2809 is a promising potential treatment for metabolic dysfunction-associated steatohepatitis, a liver ...
Los Angeles Capital Management LLC trimmed its holdings in shares of Viking Therapeutics, Inc. (NASDAQ:VKTX – Free Report) by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback